NIOX VERO Nasal Application in Primary Ciliary Dyskinesia

Inclusion criteria

• Male and female patients 5 years and older.
• Anatomically, is able to complete the nasal NO measurements in both nostrils.
• Cohort 1 - PCD Patients: Patients must have a confirmed diagnosis of PCD from one of the PCD diagnostic centres based on clinical phenotype PLUS diagnosis made by at least 1 of the following (the specifics about how diagnosis was made must be documented in their medical file):

• A nasal biopsy or scraping showing a hallmark PCD defect such as, an outer (+/- inner) dynein arm defect, microtubule defect, or
• A genetic test positive for bi-alleilic mutations in a known PCD-causing gene associated with the diagnosis of PCD (e.g., ARMC4, C21orf59, CCDC39, CCDC40, CCDC65, CCDC164, CCDC103, CCDC114, CCDC151, CCNO, DNAAF1 (LRRC50), DNAAF2 (KTU), DNAAF3, DNAH5, DNAH11, DNAI1, DNAI2, DNAL1, DYX1C1, HEATR2, HYDIN, LRRC6, MCIDAS, NME8 (TXNDC3), ODA/IDA, OFD1, RPGR, RSPH3, RSPH4A, RSPH9, SPAG1, ZMYND10), or
• EU Centres Only: A low nasal NO (determined by a chemiluminescent analyser) plus either:

• at least 2 separate occasions with 'hallmark' changes on high-speed video microscopy, or
• demonstration of mislocalisation of ciliary proteins by immunofluorescence microscopy.
• Cohort 2 - Healthy Patients: Healthy, non-atopic, non-smoking patients (defined as patient with no airway or immune problems, no recent significant injury, no systemic infection, no systemic inflammation, no allergies or asthma).

Exclusion criteria

• Currently smokes or it has been less than 6 months from quitting.
• Has had a nose bleed within the past 2 weeks.
• Has acute respiratory symptoms or signs of an upper or lower respiratory tract infection.
• Use of nasal medication as described below:

• Xolair ≤180 days prior to nNO measurement
• Oral or Systemic Corticosteroids ≤30 days prior to nNO measurement
• Inhaled, nebulized, or intranasal corticosteroids ≤30 days prior to nNO measurement
• Nasal or oral decongestants or antihistamines ≤14 days prior to nNO measurement
• Leukotriene receptor antagonists ≤30 days prior to nNO measurement
• Has an obstruction or anatomy that prevents a nasal measurement from being performed (as confirmed by simple visual inspection by the Investigator).
• Has Cystic Fibrosis.
• Has a documented primary or acquired immunodeficiency.
• Is undergoing treatment with NO-releasing drugs (such as nitrates or molsidomine).
• Has had food or beverage intake (other than water) or has participated in strenuous exercise within 1 hour of nasal NO measurement
• Is unwilling or unable to provide consent to participate (self, parent or legal guardian).
• PCD Patients Only: Has mutations with RSPH1 since nasal NO may not be low in these patients.
• PCD Patients Only: Has not had a standard clinical evaluation to address other potential causes of chronic oto-sino- pulmonary disease.
• Healthy Patients Only: Atopy or the presence of any of the following: a recent significant injury (i.e., within 1-2 weeks), systemic inflammation, airway or immune problem, asthma or allergies.
• In the US only: Patients may not be related to a member of the Study Personnel.